

Literatur für onkologie heute 09/2021

SCHWERPUNKT: Leberzellkarzinom

Therapiewandel beim Hepatozellulären Karzinom (S. 42–47)

A. Schindler, F. van Bömmel, F. Lordick und T. Berg

1. Bray et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*; 68(6): 394–424
2. Llovet et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; 359: 378–90
3. Finn et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med* 2020; 382: 1894–905
4. Schönfeld et al. Epidemiologie des hepatozellulären Karzinoms in Deutschland. *Onkologe*; 24: 653–58
5. International Agency for Research on Cancer. GLOBOCAN 2018. IARC 2020
6. Llovet J et al. Hepatocellular Carcinoma. *Disease Primer Nature* 2021, 7: 6
7. European Association of the Study of the Liver. EASL Clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2018; 69(1): 182–236
8. Kudo et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. *Lancet* 2018; 391: 1163–73
9. Bruix et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double blind, placebo-controlled, phase 3 trial. *Lancet* 2017; 389: 56–66
10. Abou-Alfa et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. *N Engl J Med* 2018; 379: 54–63
11. Zhu et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; 20: 282–96
12. Yau et al. LBA38_PRCheckMate 459: A randomized, multicenter phase III study of nivolumab(NIVO) vs sorafenib (SOR) as first-line (1L) treatments in patients (pts) with advanced hepatocellular carcinoma (aHCC). *Ann Oncol* 2019
13. El-Khoueiry et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non comparative, phase 1/2 dose escalation and expansion trial. *Lancet* 2017; 389: 2492–502
14. Yau et al. Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. *JAMA Oncol* 2020; 6
15. Zhu et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open label phase 2 trial. *Lancet Oncol* 2018; 19: 940–52
16. Finn et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. *J Clin Oncol* 2020; 38: 2960–70
17. Lee et al. Randomised efficacy and safety results for atezolizumab (ATEZO) + bevacizumab (BEVA) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). *Ann Oncol* 2019; 30:Suppl 5:v875. Abstract
18. Chiang D.Y. et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. *Cancer Res* 2008; 68: 6779–88
19. Sia D. et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. *Gastroenterology* 2017; 153: 812–26

20. Vogel et al. Clinical value of atezolizumab+bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis. *J Clin Oncol* 2020; 38: 4585
 21. Gordon et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. *J Clin Oncol* 2020, 38: 4317–45
 22. Kudo et al. Randomised, multicenter prospective trial of transarterial chemoembolization (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. *Gut* 2020; 69(8): 1492–501
 23. Ricke et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma (SORAMIC). *J Hepatol* 2019; 71(6): 1164–74
 24. Chow et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. *J Clin Oncol* 2018; 36(19): 1913–21
 25. Vilgrain et al. Radioembolisation with yttrium-90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): an open-label randomized controlled phase 3 trial. *Lancet Oncol* 2017; 18: 1624–36
 26. Finn RS et al. IMbrave150: updated overall survival data from a global, randomised, open-label Phase III study of atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma. *ASCO GI* 2020; Abstract #267
-